肌肉减少症生物标志物研究新进展  

Recent advances in biomarkers of sarcopenia

作　　者：杜红珍[1,2] 孙克娟 李增宁[1,2] Du Hongzhen;Sun Kejuan;Li Zengning(Department of Nutrition,First hospital of Hebei Medical University,Shijiazhuang 050031,Hebei,China;Hebei Provincial Key Laborato-ry of Nutrition and Health,Shijiazhuang 050031,Hebei,China;Nursing Department,First hospital of Hebei Medical University,Shijia-zhuang 050031,Hebei,China)

机构地区：[1]河北医科大学第一医院营养科,石家庄050031 [2]河北省营养与健康重点实验室,石家庄050031 [3]河北医科大学第一医院护理部,石家庄050031

出　　处：《肿瘤代谢与营养电子杂志》2022年第2期134-140,共7页Electronic Journal of Metabolism and Nutrition of Cancer

基　　金：河北省重点研发计划(21377728D);河北省卫生健康委医学适用技术跟踪项目(GZ2022055)。

摘　　要：肌肉减少症是一种进行性、广泛性的骨骼肌质量及力量下降,以及由此导致的体能下降、生活质量下降和死亡等不良后果的综合征,属于一种肌肉疾病,有原发性肌肉减少症和继发性肌肉减少症两型。肌肉减少症与活动障碍、跌倒、低骨密度及代谢紊乱密切相关,具有较高的发病率和广泛的不良结果,肌肉减少症患者生活质量下降,给个人、家庭带来沉重的经济负担。但肌肉减少症在临床实践中经常被诊断不足,近年来,基于肌肉减少症发病机制的研究,多种潜在的生物学标志物被提出,如肌肉生长抑制素、循环C-末端聚集蛋白片段与Ⅲ型前胶原蛋白N末端肽等,它们通常与特定的致病机制和/或表型有关,有效的生物标志物可促进肌肉减少症的早期诊断,分析疾病的严重程度,改善预后,并对相关治疗效果进行评估,但目前尚无有效的生物标志物标准。本文重点综述了一些近期国内外关注度较高的肌肉减少症生物标志物的最新进展,为科学、合理地评价患者肌肉减少症的状况及后续采取恰当的干预治疗措施提供理论依据。Sarcopenia is a progressive and widespread decline in skeletal muscle mass and strength, as well as the resulting decline in physical fitness, quality of life, and death. There are two types of sarcopenia, primary and secondary sarcopenia. Sarcopenia is closely related to dysactivity, falls, low bone density and metabolic disorders. It has a high incidence and a wide range of adverse results. The quality of life of patients with sarcopenia decreases, which brings a heavy economic burden to individuals and families, and even serious adverse effects on social public health. However, sarcopenia is often underdiagnosed in clinical practice. In recent years, based on the research on the pathogenesis of sarcopenia, a variety of potential biomarkers have been proposed, such as myostatin, circulating C-terminal aggregate protein fragments and typeⅢprocollagen N-terminal peptides, etc., which are usually related to specific pathogenic mechanisms and/or phenotypes. Effective biomarkers can promote the early diagnosis and prognosis of sarcopenia, and analyze the severity of the disease,and the effect of treatment is evaluated, but there is currently no effective biomarker standard. This article focuses on the recent advances in biomarkers of sarcopenia that have received high attention at home and abroad, and provide a reference for the improvement of patients with sarcopenia. It will provide a theoretical basis to help many clinicians reasonably evaluate the patient’s sarcopenia status and take appropriate intervention measures to solve the troubles.

关 键 词：肌肉减少症 生物标志物 肌肉质量 

分 类 号：R685[医药卫生—骨科学]